Walleye Capital
ATYR

Walleye Capital’s aTyr Pharma ATYR Stock Holding History

Walleye Capital’s Portfolio ATYR Stock Details ATYR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-750,000
Closed -$1.64M – 4445
2022
Q4 		$1.64M Buy
750,000
+343,114
+84% +$809K 0.03% 691
2022
Q3 		$1.22M Buy
+406,886
New +$1.36M 0.02% 836

Other funds holding ATYR

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
TM
Tikvah Management Charlotte, North Carolina $323M AUM 69.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Walleye Capital's ATYR Position: Q1 2023 in Review

Walleye Capital sold out of aTyr Pharma (ATYR) in Q1 2023, closing a stake of 750,000 shares — an estimated $1.64M sold.

Walleye Capital first reported a position in ATYR in Q3 2022 and held it in 2 quarters. The position peaked at $1.64M in Q4 2022. 37 funds tracked by Wall St. Rank hold ATYR as of Q1 2023.

  • Walleye Capital reported no remaining aTyr Pharma position as of Q1 2023 after selling out during the quarter.
  • Walleye Capital sold 750,000 aTyr Pharma shares in Q1 2023, an estimated $1.64M.
  • Walleye Capital first reported a position in aTyr Pharma in Q3 2022 and held it in 2 quarters.
  • Walleye Capital's aTyr Pharma position peaked at $1.64M in Q4 2022.
  • 37 funds tracked by Wall St. Rank held aTyr Pharma as of Q1 2023.

Based on Walleye Capital's 13F filing for Q1 2023, filed 15 May 2023.